Abstrato

Utility of Medihope as an addon therapy for Covid 19 patients: An Open labeled, Non-Randomized, Multicentric, Phase III Clinical.

Ram Katkar

 Utility of Medihope as an addon therapy for Covid 19 patients: An Open labeled, Non-Randomized, Multicentric, Phase III Clinical. Objectives: Primary objective: To compare the efficacy of Is Medihope with standard treatment VS Standard treatment alone with respect to changes in SpO2 levels and X ray chest of COVID 19 positive patients admitted to Dedicated Covid Hospital, Loni and Swargiya Shrimati Sindhutai Vikhe Patil, Covid Care Center, Ahmednagar. Secondary objective: To compare the efficacy of Is Medihope with standard treatment VS to Standard treatment alone with respect to changes in temperature, respiratory symptoms and change in CBC & Duration of stay of COVID 19 positive patients admitted to Dedicated Covid Hospital, Loni and Swargiya Shrimati Sindhutai Vikhe Patil, Covid Care Center, Ahmednagar. Outcome measures Primary: SpO2 levels X ray chest Secondary: Temperature, respiratory symptoms and change in CBC & Duration of stay Population: Patients infected with Covid 19 detected by RTPCR (Real-Time Reverse Transcription Polymerase Chain), TrueNat or Corona Rapid Test admitted and receiving treatment in Dedicated Covid Hospital, Loni and Swargiya Shrimati Sindhutai Vikhe Patil, Covid Care Center, Ahmednagar. Phase: III Number of Sites: Multi-center Study Design: Open label, Non-Randomized Study Duration: 1 year Participant’s participation Duration: 7 days Description of study intervention: A. ICMR Standard treatment B. ICMR Standard treatment + Medihope supplementation 4 | P a g e Results The groups were comparable with respect to gender and age. Thus there was lesser increase in the WBC in Mediphope group, indicating a better prognosis, although statistically nonsignificant. There was earlier fall in temperature and Respiratory rate, higher rise in Spo2 levels in patients of Medihope group as compared to that of the Standard group. There was earlier relief from symptoms among the patients of Medihope group as compared to the Standard group. The outcomes were related to mean duration of hospital stay and changes in Chest X ray were comparable among the groups. Conclusion Medihope may be advocated in patients with mild and moderate severity patients of Corona infection along with Standard treatment as add on therapy for earlier mitigation of deranged temperature, Respiratory rate, WBC count, Spo2 levels and symptoms.